Dachaigh › Rhabdomyosarcoma
Sgrùdaidhean clionaigeach Rhabdomyosarcoma a’ fastadh anns na SA
Tha 26 sgrùdaidhean airson Rhabdomyosarcoma a’ fastadh phàirtichean aig làraichean air feadh nan Stàitean Aonaichte.
Bailtean leis na sgrùdaidhean as motha
- Houston, TX6 sgrùdaidhean
- Memphis, TN6 sgrùdaidhean
- Washington, DC5 sgrùdaidhean
- Salt Lake City, UT4 sgrùdaidhean
- Philadelphia, PA4 sgrùdaidhean
- Boston, MA4 sgrùdaidhean
- Seattle, WA3 sgrùdaidhean
- Birmingham, AL3 sgrùdaidhean
- Dallas, TX3 sgrùdaidhean
- Baltimore, MD3 sgrùdaidhean
- The Bronx, NY3 sgrùdaidhean
- Aurora, CO3 sgrùdaidhean
Le stàit
- Alabama3 sgrùdaidhean
- California7 sgrùdaidhean
- Colorado3 sgrùdaidhean
- Florida3 sgrùdaidhean
- Maryland4 sgrùdaidhean
- Massachusetts4 sgrùdaidhean
- New York4 sgrùdaidhean
- Ohio5 sgrùdaidhean
- Pennsylvania5 sgrùdaidhean
- Sgìre Cholumbia4 sgrùdaidhean
- Tennessee8 sgrùdaidhean
- Texas9 sgrùdaidhean
- Utah4 sgrùdaidhean
- Washington3 sgrùdaidhean
Sgrùdaidhean air an ùrachadh o chionn ghoirid
Teacsa sgrùdaidh oifigeil (Beurla)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
A’ fastadhÌre 1
Aoisean 3 gu 39 · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
A’ fastadhÌre 1
24 Months – 18 Years · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
A’ fastadhÌre 1/2
Suas gu aois 30 · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
A’ fastadhÌre 3
Suas gu aois 50 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
A’ fastadh
Gach aois · Gach gnè · Air ùrachadh 21 Lùna 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
A’ fastadhÌre 1
Aoisean 1 gu 23 · Gach gnè · Air ùrachadh 13 Lùna 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
A’ fastadhÌre 1
Aoisean 1 gu 21 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT04715191Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT05210374Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
A’ fastadhÌre 1 tràth
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 31 Iuch 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
A’ fastadhÌre 1/2
Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 22 Iuch 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
A’ fastadh
Suas gu aois 39 · Gach gnè · Air ùrachadh 13 Iuch 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
A’ fastadhÌre 1/2
6 Months – 25 Years · Gach gnè · Air ùrachadh 30 Ògmh 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 17 Ògmh 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
A’ fastadhÌre 2
Suas gu aois 22 · Gach gnè · Air ùrachadh 15 Ògmh 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
A’ fastadhÌre 1/2
6 Months – 30 Years · Gach gnè · Air ùrachadh 2 Ògmh 2026 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
A’ fastadhÌre 1
Suas gu aois 21 · Gach gnè · Air ùrachadh 19 Cèit 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
A’ fastadhÌre 1/2
12 Months – 30 Years · Gach gnè · Air ùrachadh 19 Cèit 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
A’ fastadhÌre 1
Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 15 Gibl 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
A’ fastadhÌre 2
Aoisean 1 gu 50 · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
A’ fastadhÌre 1/2
Aoisean 12 gu 49 · Gach gnè · Air ùrachadh 19 Gearr 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
A’ fastadhÌre 1
Aoisean 1 gu 26 · Gach gnè · Air ùrachadh 17 Gearr 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
A’ fastadhÌre 1
Aoisean 1 gu 25 · Gach gnè · Air ùrachadh 22 Faoi 2026 · NCT04995003Molecular Analysis Of Solid Tumors
A’ fastadhSgrùdadh amharc
Suas gu aois 25 · Gach gnè · Air ùrachadh 12 Samh 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
A’ fastadhÌre 1
Suas gu aois 21 · Gach gnè · Air ùrachadh 3 Samh 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
A’ fastadhÌre 1
7 Months – 21 Years · Gach gnè · Air ùrachadh 16 Dàmh 2025 · NCT02508038Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.